Bioline Launches the Full Range of EPIK™ miRNA Assays
January 09 2017 - 12:05PM
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the
EPIK™ miRNA Select Assays, originally developed for the study of
individual microRNA (miRNA) molecules. In collaboration with
MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March
2016 and this has now been increased to include all of the
organisms listed on the miRBase release 21, which represents over
27,000 miRNA assays. Recent studies continue to show the clinical
value of individual miRNA molecules which are released from tissues
and cells. The expression of certain individual miRNA molecules
correlates with specific disease conditions making them promising
biomarker candidates for the early detection of disease, prognosis
and monitoring of treatment in both humans and other organisms.
Each assay is designed by MiRXES in silico using
proprietary thermodynamics-based algorithms and include miRNA
specific reverse transcriptase primers and hemi-nested real-time
PCR primers along with Bioline reverse transcriptase, SensiSMART™
with SYBR®1 Green and highly optimized buffers. The resulting
assays enable detection of extremely low levels of miRNA with very
high specificity and allow the discrimination between closely
related miRNA sequences.
Marco Calzavara, President of Bioline commented,
“I am very pleased to announce the expansion of the EPIK miRNA
Select Assays. The increased portfolio of high quality miRNA assays
will help even more researchers with miRNA expression profiling,
quantification and in biomarker discovery.”
Richard L. Eberly, President, Chief Commercial
Officer, stated, “The release of the full range of EPIK miRNA
Select Assays and their enhanced performance are an important
addition to our portfolio. They increase the flexibility of this
highly useful research tool by allowing more of our life science
customers to create accurate and non-invasive molecular diagnostic
assays in humans and in other organisms.”
About Meridian Bioscience,
Inc. Meridian is a fully integrated life science
company that develops, manufactures, markets and distributes a
broad range of innovative diagnostic test kits, rare reagents,
specialty biologicals and components. Utilizing a variety of
methods, our diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical
conditions, such as infections and lead poisoning. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's diagnostic products
are designed to enhance patient well-being while reducing the total
outcome costs of health care. Meridian has strong market positions
in the areas of gastrointestinal and upper respiratory infections
and blood lead level testing. In addition, Meridian is a supplier
of rare reagents, specialty biologicals and components used by
organizations in the life science and agribio industries engaged in
research and by companies as components in the manufacture of
diagnostics. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics
manufacturers and agribio companies in more than 70 countries
around the world. The Company’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:For more information
about Bioline, please visit http://www.bioline.com.
__________________________________________1 SYBR is a
registered trademark of Thermo Fisher Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
rick.eberly@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024